Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider Ross Moat Sells 75,608 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Ross Moat sold 75,608 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The stock was sold at an average price of $93.13, for a total transaction of $7,041,373.04. Following the sale, the chief operating officer directly owned 10,294 shares in the company, valued at approximately $958,680.22. The trade was a 88.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ross Moat also recently made the following trade(s):

• On Monday, November 2nd, Ross Moat sold 27,977 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $92.36, for a total transaction of $2,583,955.72.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock traded up $2.49 during trading hours on Tuesday, hitting $93.29. The company had a trading volume of 1,021,631 shares, compared to its average volume of 705,858. The company’s 50-day moving average is $79.39 and its two-hundred day moving average is $60.29. The company has a market cap of $7.28 billion, a P/E ratio of 71.76 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a twelve month low of $37.02 and a twelve month high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The firm had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. Sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.26 EPS for the current year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $1,161,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth $631,000. Handelsbanken Fonder AB acquired a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth $1,343,000. The Manufacturers Life Insurance Company grew its position in Kiniksa Pharmaceuticals International by 56.7% in the 1st quarter. The Manufacturers Life Insurance Company now owns 63,346 shares of the company’s stock valued at $3,050,000 after buying an additional 22,917 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in Kiniksa Pharmaceuticals International by 213.5% in the 1st quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock valued at $23,197,000 after buying an additional 327,595 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analysts Set New Price Targets

KNSA has been the topic of several research reports. Citigroup raised their price objective on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. upped their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday. Canaccord Genuity Group upped their target price on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Wells Fargo & Company raised their price target on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Finally, Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $100.57.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.